The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells

The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells

Background: The third-generation epidermal growth factor receptor (EGFR) inhibitor, Osimertinib, is used to treat non-small cell lung cancer (NSCLC) patients with tyrosine kinase inhibitor (TKI) resistance caused by acquired EGFR T790M mutation. However, patients eventually develop resistance agains...

Full description

Bibliographic Details
Main Authors: Wen-Chien Huang, Vijesh Kumar Yadav, Wei-Hong Cheng, Chun-Hua Wang, Ming-Shou Hsieh, Ting-Yi Huang, Shiou-Fu Lin, Chi-Tai Yeh, Kuang-Tai Kuo
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Cancers
Subjects:
non-small cell lung cancer (NSCLC)
Osimertinib resistance
MEK inhibitor Trametinib
miR-21
cancer-associated fibroblasts (CAFs)
human lung fibroblasts (HLFs)
Online Access:https://www.mdpi.com/2072-6694/13/23/6005

Internet

https://www.mdpi.com/2072-6694/13/23/6005

Similar Items